BeyondSpring Pharmaceuticals
2 known investors
Beyond Spring Pharmaceuticals develops Plinabulin, a brain-penetrant immune modulator that activates dendritic cells through a differentiated tubulin-binding mechanism, intended to enhance antigen presentation and T cell activation for select tumor types. The compound demonstrates clinical benefit in extending overall survival and reducing severe chemotherapy-related neutropenia.
Investors · 2
In the news
Frequently asked questions
- What does BeyondSpring Pharmaceuticals do?
- Beyond Spring Pharmaceuticals develops Plinabulin, a brain-penetrant immune modulator that activates dendritic cells through a differentiated tubulin-binding mechanism, intended to enhance antigen presentation and T cell activation for select tumor types. The compound demonstrates clinical benefit in extending overall survival and reducing severe chemotherapy-related neutropenia.
- Who are BeyondSpring Pharmaceuticals's investors?
- BeyondSpring Pharmaceuticals's investors include Decheng Capital, Sangel Capital.